NCT06149559 2026-04-14
roMyG
UCB Pharma
Phase 2/3 Recruiting
Clinical Trials
12 trialsNCT06055959 2026-04-13
ziMyG
UCB Pharma
Phase 2/3 Recruiting
NCT06193889 2026-04-06
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Kyverna Therapeutics
Phase 2/3 Recruiting
NCT05265273 2026-03-13
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
Phase 2/3 Recruiting
NCT04833894 2026-02-18
ADAPT Jr
argenx
Phase 2/3 Recruiting
NCT05374590 2026-02-02
ADAPT Jr +
argenx
Phase 2/3 Enrolling by invitation
NCT06392386 2025-12-05
ADAPT Jr SC
argenx
Phase 2/3 Recruiting
NCT06836973 2025-03-25
Blinatumomab for Treatment of Refractory Myasthenia Gravis
Da, Yuwei, M.D.
Phase 2/3 Not yet recruiting
NCT06447597 2024-10-31
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3 Recruiting
NCT05716035 2024-01-22
tMG-E
Tang-Du Hospital
Phase 2/3 Unknown
NCT03914638 2020-04-06
BETA-MG
University of Aarhus
Phase 2/3 Unknown
NCT03165435 2018-05-30
A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis
CuraVac
Phase 2/3 Withdrawn